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11Summary
A 67-year-old woman presented with a generalised rash associated with weight loss and resting tachycardia. She had 
a recent diagnosis of diabetes mellitus. Biochemical evaluation revealed elevated levels of circulating glucagon and 
chromogranin B. Cross-sectional imaging demonstrated a pancreatic lesion and liver metastases, which were octreotide-
avid.Biopsyoftheliverlesionconfirmedadiagnosisofwell-differentiatedgrade2pancreaticneuroendocrinetumour,
consistentwithmetastaticglucagonoma.Serialechocardiographycommenced4 yearsbeforethisdiagnosisdemonstrated
a progressive left ventricular dilatation and dysfunction in the absence of ischaemia, suggestive of glucagonoma-
associated dilated cardiomyopathy. Given the severity of the cardiac impairment, surgical management was considered 
inappropriateandsomatostatinanaloguetherapywasinitiated,affectingclinicalandbiochemicalimprovement.Serial
cross-sectionalimagingdemonstratedstabledisease2 yearsafterdiagnosis.Leftventriculardysfunctionpersisted,
however, despite somatostatin analogue therapy and optimal medical management of cardiac failure. In contrast to 
previous reports, the case we describe demonstrates that chronic hyperglucagonaemia may lead to irreversible left 
ventricular compromise. Management of glucagonoma therefore requires careful and serial evaluation of cardiac status.
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Learning points:
•• Inrarecases,glucagonomamaypresentwithcardiacfailureasthedominantfeature.Significantcardiac
impairment may occur in the absence of other features of glucagonoma syndrome due to subclinical chronic 
hyperglucagonaemia.
•• A diagnosis of glucagonoma should be considered in patients with non-ischaemic cardiomyopathy, particularly 
those with other features of glucagonoma syndrome.
•• Cardiac impairment due to glucagonoma may not respond to somatostatin analogue therapy, even in the context 
of biochemical improvement.
•• All patients with a new diagnosis of glucagonoma should be assessed clinically for evidence of cardiac failure and, 
if present, a baseline transthoracic echocardiogram should be performed. In the presence of cardiac impairment 
these patients should be managed by an experienced cardiologist.
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Background
We describe dilated cardiomyopathy as a rare clinical 
manifestation of the glucagonoma syndrome. In contrast 
with previous reports, cardiac function did not improve 
following initiation of somatostatin analogue therapy, 
despite biochemical resolution of hyperglucagonaemia. 
We recommend that all patients diagnosed with the 
glucagonoma syndrome undergo regular clinical 
examination for the presence of cardiac dysfunction, and 
if detected, get it thoroughly investigated and managed 
by an experienced cardiologist.
Case presentation
A 67-year-old female of Europid descent presented to the 
dermatology service with a 2-year history of a fleeting, 
generalised rash. The rash was erythematous with brown 
crusting, scaly and non-itchy, and particularly affected the 
legs, perineum and lower back (Fig. 1A). The appearances 
were in keeping with necrolytic migratory erythema, 
prompting referral to endocrinology.
On further inquiry, the patient reported profound 
weight loss, inappetence, reduced exercise tolerance, 
palpitations and peripheral oedema, all evolving over 
a 2-year period. There was no history of flushing, chest 
or abdominal pain, change in bowel habit or jaundice. 
A diagnosis of early diabetes mellitus had been made 
2  years prior, which was well controlled with a single 
oral hypoglycaemic agent (40 mg gliclazide once daily). 
The patient reported pre-existing hypertension and 
osteoporosis. Notably, she had been investigated 4 years 
ago for left ventricular impairment of unknown aetiology. 
There was no history of venous thromboembolic disease. 
Regular medications included gliclazide, bisoprolol, 
alendronate, calcium and vitamin D. There was no family 
history of endocrinopathy (including multiple endocrine 
neoplasia), malignancy or premature cardiovascular 
disease. The patient consumed fewer than 10 units of 
alcohol per week and was a lifelong non-smoker.
On clinical examination the patient was slim with 
a BMI of 18.2 kg/m2. She was tachycardic (resting heart 
rate ranging between 80 and 100 beats per minute) 
and hypotensive (blood pressure ranging from 80/40 
Figure 1
Clinical and radiological features at diagnosis. (A) Representative photograph of the patient’s rash at presentation (gluteal region). (B and C) Cross-
sectional imaging at presentation, showing pancreatic (B) and hepatic (C) lesions. (D) Octreotide scintigraphy showing octreotide avidity in the pancreas 
and liver segment VI (anterior and posterior views). (E) Gadolinium-enhanced MRI images of the pancreatic and hepatic lesions.
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to 100/60 mmHg). Auscultation of the heart revealed 
normal S1 and S2 with no added sounds. Bilateral pitting 
oedema was appreciated in the lower limbs. Respiratory 
and abdominal examinations were unremarkable. 
Examination of the skin revealed an ongoing widespread 
blistering rash with areas of confluence covering the back 
and gluteal regions.
Investigation
Biochemical investigations revealed markedly elevated 
fasting plasma glucagon (>500 pmol/L; normal range: 
0–50 pmol/L) and chromogranin B (526 pmol/L; normal 
range: 0–150 pmol/L) (Table  1). Haematological indices 
were unremarkable.
Cross-sectional imaging by computed tomography 
(CT) demonstrated a 51 × 30 mm heterogeneous enhancing 
mass lesion in the body of the pancreas, as well as a 
15 mm nodule in the head of the pancreas (Fig. 1B). Low 
attenuation lesions were seen in segments IV and VI of the 
liver (Fig. 1C), in addition to several enlarged mesenteric 
lymph nodes. Left ventricular dilatation, interlobular 
septal thickening and a left pleural effusion were noted.
Collectively, the clinical, biochemical and radiological 
findings were suggestive of a metastatic pancreatic 
glucagonoma. An octreotide scan demonstrated octreotide 
avidity in the pancreatic body and liver segment VI 
(Fig.  1D). Similarly, gadolinium-enhanced magnetic 
resonance imaging (MRI) of the liver demonstrated 
restricted diffusion in segment VI only, indicating that 
the other two liver lesions were benign cysts (Fig.  1E). 
Ultrasound-guided biopsy of the segment VI lesion 
confirmed a metastatic well-differentiated neuroendocrine 
tumour, with strong diffuse staining for synaptophysin, 
CD56 and CDX2; patchy but strong immunopositive 
staining for PAX8; and weak staining for chromogranin 
A. There was no immunopositive staining for glucagon or 
TTF-1. MIB-1 index was 2–5%. The tumour was classified 
as a well-differentiated grade 2 pancreatic neuroendocrine 
tumour (NET) with liver metastases.
The abnormal cardiac appearances on CT prompted 
further evaluation. An electrocardiogram (ECG) 
demonstrated sinus tachycardia with left bundle branch 
block. Transthoracic echocardiography revealed severe 
left ventricular (LV) dysfunction and dilatation, with an 
ejection fraction of 20–25%, and a left ventricular internal 
diameter in diastole (LVIDd) of 7.0 cm (normal range: 3.5–
5.6 cm), consistent with dilated cardiomyopathy (DCM). 
Left atrial dilatation was also noted. Right ventricular 
size and function were normal. There was no evidence of 
significant valvular pathology (mild mitral regurgitation 
only). Indeed, echocardiography performed 4 years prior 
to diagnosis had similarly demonstrated severely reduced 
LV function with mild LV dilatation (LVIDd 5.5 cm). 
Cardiac MRI subsequently confirmed a reduced LV 
ejection fraction with normal right heart function. There 
were no radiological features of myocardial oedema, 
scar or fibrosis. Gadolinium perfusion was normal, with 
no late gadolinium enhancement. Collectively these 
findings excluded ischaemic cardiomyopathy. There 
was no history of arrhythmia. There were no clinical or 
radiological features to suggest infiltrative cardiac disease 
or myocarditis. Of note, however, a viral screen was not 
undertaken at the time of initial diagnosis. There was 
no history of excessive alcohol consumption or use of 
cardiotoxic medications, nor was there a family history 
of cardiomyopathy. A diagnosis of glucagonoma-induced 
cardiomyopathy was therefore made.
Treatment
The patient’s severely impaired LV function and general 
frailty were felt to be prohibitive for safe surgery, and 
a medical therapy with a somatostatin analogue was 
therefore recommended. Lanreotide (120 mg every 
28 days) was initiated, with nutritional support provided 
Table 1 Biochemical evaluation at baseline and during somatostatin analogue therapy.
 
Reference range
Duration of lanreotide treatment (months)
Baseline 6 months 24 months
Glucagon (pmol/L) 0–50 >500 67 100
Chromogranin A (pmol/L) 0–60 35 16 27
Chromogranin B (pmol/L) 0–150 526 308 368
Vasoactive intestinal peptide (pmol/L) 0–30 6 3 3
Somatostatin (pmol/L) 0–150 38 20 35
Gastrin (pmol/L) 0–40 28 8 35
Pancreatic polypeptide (pmol/L) 0–300 151 40 63
All gut hormones were assayed in the fasting state.
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by a specialist dietician. Cardiac function was optimised 
medically using a combination of beta-blockade, 
angiotensin converting enzyme inhibition (later switched 
to angiotensin II receptor blockade) and spironolactone.
Outcome and follow-up
Three months after initiation of lanreotide, the patient 
reported significant clinical improvement including 
resolution of the rash, improved appetite, weight gain 
and minimal peripheral oedema. Her exercise tolerance 
was stable and there was no subjective dyspnoea. Repeat 
biochemical investigation after 6  months of lanreotide 
therapy demonstrated marked improvement in both 
fasting glucagon (67 pmol/L) and chromogranin B 
(308 pmol/L) concentrations (Table  1). Cross-sectional 
imaging showed stable appearances of the primary 
pancreatic tumour, hepatic metastases and mesenteric 
lymph nodes; however, there was persistent dilatation of 
the left ventricle with worsening pulmonary congestion. 
Consistent with this, repeat echocardiography 
demonstrated an unchanged LVEF and LVIDd, indicating 
ongoing severe LV impairment (Table 2).
Eleven months after commencement of lanreotide 
treatment, the patient presented to her local hospital 
with worsening lethargy, tachycardia and clinical 
features suggestive of acute decompensation of cardiac 
failure. Cross-sectional imaging demonstrated new 
moderate bilateral pleural effusions, cardiomegaly 
with severe tricuspid regurgitation and progressive 
pulmonary congestion. Echocardiography demonstrated 
an LVEF of 20–25% and LVIDd of 7.3 cm, indicating 
ongoing severe LV failure. There was no evidence of 
an acute ischaemic event. Following further medical 
optimisation (furosemide 40 mg, spironolactone 25 mg, 
bisoprolol 5 mg, ramipril 2.5 mg and losartan 50 mg), 
her symptoms returned to their baseline level and 
she reported good exercise tolerance. Treatment with 
lanreotide continued.
At her latest clinical review, 24  months after 
commencement of lanreotide, the patient reported 
ongoing symptomatic control and fasting gut-hormone 
levels were stable (Table  1). Surveillance imaging by 
contrast enhanced CT demonstrated stable pancreatic 
disease, however repeat echocardiography continued 
to show a severely dilated left ventricle with severe LV 
dysfunction despite optimisation of medical therapy 
(Fig. 2). NT pro-BNP was markedly elevated at 15 189 pg/mL. 
Biventricular pacemaker insertion is planned.
Discussion
Glucagonomas are rare tumours with an annual 
incidence of 1 per 20–40 million population (1). 80% are 
sporadic, with the remainder associated with inherited 
tumour predisposition syndromes such as multiple 
endocrine neoplasia type 1 (MEN-1). Patients may be 
asymptomatic or present with a range of features typical 
of the glucagonoma syndrome, including necrolytic 
migratory erythema, weight loss, glucose intolerance, 
painful glossitis, stomatitis, diarrhoea, thromboembolic 
disease and psychiatric illness (1). Less commonly 
recognised are paraneoplastic phenomena associated with 
impaired processing of the proglucagon prohormone 
and aberrant tumoural secretion of proglucagon-derived 
peptides, including GLP-1 and GLP-2, which may induce 
hyperinsulinaemic hypoglycaemia and gastrointestinal 
dysfunction, respectively (1, 2). In addition, in three 
Table 2 Serial echocardiography at baseline and during 
somatostatin analogue therapy.
Duration of  
treatment (months) LVIDd, cm LVEF, %
−46 5.5 ‘Severely reduced 
systolic function’
0 7.0 20–25
6 7.2 28
13 7.3 20–25
21 6.9 28
LVIDd, left ventricular internal diameter in diastole; LVEF, left ventricular 
ejection fraction.
Figure 2
Echocardiographic features of dilated cardiomyopathy before and after 
somatostatin analogue therapy. Representative four-chamber views 
showingleftventriculardilatationatbaseline(left)andafter21 monthsof
lanreotide therapy (right).
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previously published reports, decompensated heart failure 
and dilated cardiomyopathy were posited as rare clinical 
manifestations of the glucagonoma syndrome (3, 4, 5; 
Table 3). Herein we describe the fourth reported case of 
severe cardiac dysfunction in a patient with glucagonoma.
In 2004, Chang-Chretien and colleagues described 
the first case of acute congestive heart failure secondary 
to dilated cardiomyopathy as the presenting feature 
of glucagonoma in a 54-year-old female (3). In their 
report, biochemical investigations identified markedly 
elevated serum glucagon levels (12 times the upper limit 
of normal) in association with necrolytic migratory 
erythema, dilated cardiomyopathy, severely impaired left 
ventricular function (LVEF 15%) and resting tachycardia. 
Surgical resection of the tumour resulted in complete 
biochemical resolution and, strikingly, reversal of 
the dilated cardiomyopathy (normal LV end-diastolic 
dimensions and LVEF 55%) and normalisation of the 
heart rate. Subsequently, Demir et  al. (4) also reported 
complete resolution of dilated cardiomyopathy 1 month 
following surgical resection of a pancreatic glucagonoma. 
Zhang et  al. (5) described severe left ventricular 
dysfunction (LV ejection fraction of 10%) presenting with 
cardiogenic shock in a 51-year-old female with MEN-1, 
and a histologically confirmed metastatic glucagonoma. 
Cardiac biopsy demonstrated cardiomyocyte hypertrophy. 
Additional investigations failed to identify an alternative 
explanation for the severely impaired left ventricle and 
a diagnosis of glucagon-induced acute heart failure was 
made. Interestingly, a continuous intravenous infusion of 
octreotide resulted in an immediate improvement of LV 
function and following 3  weeks of treatment LVEF had 
improved to 45%.
In our patient, dilated cardiomyopathy was diagnosed 
4 years prior to the discovery of the glucagonoma, with 
the finding of cardiomegaly on cross-sectional imaging 
prompting cardiac re-evaluation. In the absence of an 
alternative aetiology, a diagnosis of glucagon-induced 
cardiomyopathy was made. Due to both severe cardiac 
dysfunction and metastatic disease the possibility of 
surgical resection was not pursued. Alternatively, we 
opted to treat our patient medically with somatostatin 
analogues anticipating, based on previous clinical 
reports, that, in addition to effects on tumour growth 
and hormone production, this treatment would prove 
beneficial for the LVEF. In contrast to previous reports, 
however, and despite biochemical improvement and 
tumour response to lanreotide, there was no improvement 
in LV function or dimensions. It remains possible 
that an alternative aetiology caused the development 
of dilated cardiomyopathy in our patient, thereby 
accounting for the cardiac resistance to somatostatin 
analogues. Alternatively, the prolonged exposure to 
supra-physiological glucagon levels may have induced 
irreversible pathological effects on the myocardium that 
cannot be overcome with medical treatment.
In addition to well-established actions of glucagon 
on glucose homeostasis, evidence from several pre-
clinical and clinical studies suggest that glucagon has 
direct actions on the cardiovascular system (6). Indeed, 
glucagon is a recognised treatment for beta-adrenoceptor 
antagonist overdose owing to its positive inotropic and 
chronotropic properties. Supra-physiological levels of 
glucagon may account for resting tachycardia observed in 
some patients with glucagonoma.
Glucagon mediates its effects through binding and 
activation of the glucagon receptor (GCGR), a G-protein-
coupled receptor that is expressed in a variety of tissues 
in animals and humans. In cardiac ventricles, however, 
marked interspecies differences exist with regard to 
GCGR expression. For example, functional GCGR is 
expressed in the left ventricle of mice and rats, but not in 
the left ventricle of humans (7, 8). In contrast, abundant 
glucagon-like peptide 1 receptor (GLP-1R) mRNA is 
expressed in all four chambers of the human heart, 
whereas glucagon-like peptide 2 receptor (GLP-2R) mRNA 
is expressed to a much lesser extent (7). The variability in 
GCGR expression in the human heart, along with cross 
reactivity with other related G-protein-coupled receptors, 
may explain the apparently preferential effect of supra-
Table 3 Biochemical and cardiac response to treatment of dilated cardiomyopathy associated with glucagonoma.
Reference Age (year) Sex Treatment
Glucagon levels LVEF, %
Baseline Post treatment Reference range Baseline Post treatment 
(4) 54 F Pancreatectomy 1261 pg/mL 26 pg/mL 20–100 pg/mL 15 55
(5) 51 F Octreotide infusion ND ND 10 45
(6) 64 M Distal 
pancreatectomy
97 pmol/L Normal <50 pmol/L 30 67
This case 67 F Lanreotide >500 pmol/L 67 pmol/L <50 pmol/L 20–25 28
LVEF, left ventricular ejection fraction; ND, not done.
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physiological hyperglucagonaemia, and/or aberrantly 
processed proglucagon-derived peptides, on the left 
ventricle (4, 5, 9). These observations are directly relevant 
to ongoing efforts to characterise the effects of glucagon 
and related peptides on human cardiac physiology (6).
In summary, we have reported the fourth clinical 
case of dilated cardiomyopathy and LV dysfunction in 
association with a metastatic glucagonoma. In contrast 
to previous reports, we observed no improvement in 
cardiac function following improvement in glucagon 
levels with somatostatin analogue treatment. We propose 
that dilated cardiomyopathy be considered a rare 
clinical manifestation of the glucagonoma syndrome. 
Accordingly, we recommend that individuals with 
glucagonoma undergo cardiac assessment at the time of 
diagnosis to ensure that appropriate clinical management 
and follow-up is initiated.
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